Home › Overweight › Arkansas › Little Rock
Overweight clinical trials in Little Rock, AR
5 studies for Overweight are looking for participants at sites in and around Little Rock (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
RecruitingPhase 3
- Research Site, Little Rock
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
RecruitingPhase 3
- AURORA-1 Clinical Site, Little Rock
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
RecruitingPhase 3
- AURORA-2 Clinical Site, Little Rock
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
RecruitingPhase 3Healthy volunteers welcome
- ACCOMPLISH-2 Research Site, Little Rock
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
RecruitingPhase 3
- Kailera Clinical Site, Little Rock
Overweight trials in other cities
- San Antonio, TX34 studies
- Houston, TX33 studies
- Chicago, IL28 studies
- Orlando, FL27 studies
- Las Vegas, NV23 studies
- Miami, FL23 studies
- Atlanta, GA20 studies
- Dallas, TX20 studies
- New York City, NY19 studies
- Jacksonville, FL19 studies
- Washington, DC19 studies
- Austin, TX18 studies
Other studies in Little Rock
- Schizophrenia19 studies
- Cancer (all types)14 studies
- Major Depressive Disorder14 studies
- Acute Myeloid Leukemia13 studies
- Non-Small Cell Lung Cancer13 studies
- Obesity11 studies
- Endometrial Cancer10 studies
- Type 2 Diabetes10 studies
- Depression10 studies
- Bladder Cancer9 studies
- Lung Cancer9 studies
- Heart Failure9 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.